Alec Stranahan
Stock Analyst at B of A Securities
(0.77)
# 3,952
Out of 5,012 analysts
30
Total ratings
39.13%
Success rate
-26.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $5.63 | +24.33% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $12.03 | -0.25% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $2.48 | -59.68% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $9.22 | -24.08% | 5 | Aug 20, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $193 → $192 | $183.02 | +4.91% | 4 | Jul 22, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $25.13 | +67.13% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $7.41 | +237.38% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $2.43 | +352.67% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $3.47 | +72.91% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $3.93 | +281.68% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $46.57 | +18.10% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $36.50 | -83.56% | 2 | Dec 29, 2022 |
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $5.63
Upside: +24.33%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $12.03
Upside: -0.25%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $2.48
Upside: -59.68%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $9.22
Upside: -24.08%
Krystal Biotech
Jul 22, 2025
Maintains: Buy
Price Target: $193 → $192
Current: $183.02
Upside: +4.91%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $25.13
Upside: +67.13%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $7.41
Upside: +237.38%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $2.43
Upside: +352.67%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $3.47
Upside: +72.91%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $3.93
Upside: +281.68%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $46.57
Upside: +18.10%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $36.50
Upside: -83.56%